Advertisement

Update on SAMS: Statin-associated muscle symptoms

      In 2015, the European Atherosclerosis Society (EAS) Consensus Panel published a key statement focused on statin-associated muscle symptoms (SAMS) [
      • Stroes E.S.
      • Thompson P.D.
      • Corsini A.
      • et al.
      Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis society Consensus Panel statement on assessment, aetiology and management.
      ]. This paper provided important information to assist clinicians in the assessment and management of SAMS in their routine practice, and, uniquely, appraised what is known to date regarding the pathophysiology of SAMS. Readers are referred to the publication for full details.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stroes E.S.
        • Thompson P.D.
        • Corsini A.
        • et al.
        Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis society Consensus Panel statement on assessment, aetiology and management.
        Eur. Heart J. 2015; 36: 1012-1022
        • Colloca L.
        Nocebo effects can make you feel pain.
        Science. 2017; 358: 44
        • Matthews A.
        • Herrett E.
        • Gasparrini A.
        • et al.
        Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data.
        BMJ. 2016; 353 (i3283)
        • Gupta A.
        • Thompson D.
        • Whitehouse A.
        • et al.
        Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
        Lancet. 2017; 389: 2473-2481
        • Link E.
        • Parish S.
        • Armitage J.
        • et al.
        • SEARCH Collaborative Group
        SLCO1B1 variants and statin-induced myopathy–a genome wide study.
        N. Engl. J. Med. 2008; 359: 789-799
        • Bakar N.S.
        • Neely D.
        • Avery P.
        • et al.
        Genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: a case-control study.
        Clin. Pharmacol. Therapeut. 2017 Sep 22; ([Epub ahead of print])https://doi.org/10.1002/cpt.887
        • Siddiqui M.
        • Maroteau C.
        • Veluchamy A.
        • et al.
        A common missense variant of LILRB5 is associated with statin intolerance and myalgia.
        Eur. Heart J. 2017; 38: 3569-3575
        • Reiner Ž.
        • De Backer G.
        • Fras Z.
        • et al.
        Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries–findings from the EUROASPIRE IV survey.
        Atherosclerosis. 2016; 246: 243-250
        • Colantonio L.D.
        • Huang L.
        • Monda K.L.
        • et al.
        Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries.
        JAMA Cardiol. 2017; 2: 890-895
        • Serban M.C.
        • Colantonio L.D.
        • Manthripragada A.D.
        • et al.
        Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction.
        J. Am. Coll. Cardiol. 2017; 69: 1386-1395
        • Rosenson R.S.
        • Miller K.
        • Bayliss M.
        • et al.
        The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability.
        Cardiovasc. Drugs Ther. 2017; 31: 179-186
        • Taylor B.A.
        • Sanchez R.J.
        • Jacobson T.A.
        • et al.
        Application of the statin-associated muscle symptoms-clinical index to a randomized trial on statin myopathy.
        J. Am. Coll. Cardiol. 2017; 70: 1680-1681
        • Ofori-Asenso R.
        • Jakhu A.
        • Zomer E.
        • et al.
        Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis.
        J. Gerontol. A Biol. Sci. Med. Sci. 2017 Sep 2; ([Epub ahead of print])https://doi.org/10.1093/gerona/glx169
        • World population ageing
        United Nations 2015.
        2015
        • Zhou Z.
        • Albarqouni L.
        • Breslin M.
        • et al.
        Statin-associated muscle symptoms (SAMS) in primary prevention for cardiovascular disease in older adults: a protocol for a systematic review and meta-analysis of randomized controlled trials.
        BMJ Open. 2017; 7e017587